Esperion Therapeutis.Inc. buy Bank of America Co.
Start price
15.06.23
/
50%
€1.27
Target price
15.06.24
€3.68
Performance (%)
111.30%
End price
16.06.24
€2.69
Summary
This prediction ended on 16.06.24 with a price of €2.69. With a performance of 111.30% the BUY prediction by Bank_of_America_Co_ was a big success. Bank_of_America_Co_ has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | -11.771% | -11.771% | 49.193% |
| iShares Core DAX® | -3.809% | -1.472% | 6.060% |
| iShares Nasdaq 100 | 0.487% | 2.215% | 12.682% |
| iShares Nikkei 225® | -4.418% | 4.971% | 30.914% |
| iShares S&P 500 | 0.251% | 1.225% | 9.374% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "buy" rating. They now have a $4.00 price target on the stock, up previously from $1.25.
Ratings data for ESPR provided by MarketBeat
In the thread Trading Esperion Therapeutis.Inc.
Die von Bank_of_America_Co_ gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€2.36
20.06.24
20.06.24
€2.33
20.06.25
20.06.25
-60.00%
21.06.25
21.06.25
